Forge Medical’s VasoStat Shows Favorable Outcomes in Comparative Study of Hemostasis Devices

January 27, 2021—Forge Medical, Inc. announced the publication of an investigator-initiated, randomized trial evaluating the company’s VasoStat hemostasis device in patients undergoing radial artery coronary and peripheral procedures with planned same-day discharge. The VasoStat device has received FDA clearance for radial, distal radial, and tibioperoneal hemostasis.

Robert L. Minor Jr., MD, et al published the findings in Journal of Invasive Cardiology. Dr. Minor is an interventional cardiologist affiliated with the Billings Clinic in Billings, Montana.

According to the company, the investigators reported significantly shorter times to hemostasis, higher patient satisfaction, and fewer device manipulations needed by nursing personnel in patients in the study group treated with the VasoStat versus patients in the group treated with the TR Band hemostasis device (Terumo Interventional Systems).

All patients were able to be discharged the same day as their procedure. Doppler follow-up within 60 days in all study patients confirmed radial artery patency with no events of radial artery occlusion or pseudoaneurysm, noted Forge Medical.